NASDAQ:ALNA - Allena Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allena Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.30 +0.13 (+5.99 %) (As of 02/20/2020 04:00 PM ET) Add Compare Today's Range$2.06Now: $2.30▼$2.3250-Day Range$2.05MA: $2.51▼$2.8952-Week Range$1.55Now: $2.30▼$7.95Volume386,928 shsAverage Volume275,277 shsMarket Capitalization$53.97 millionP/E RatioN/ADividend YieldN/ABeta1.74 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALNA Previous Symbol CUSIPN/A CIK1624658 Webhttp://www.allenapharma.com/ Phone617-467-4577Debt Debt-to-Equity Ratio0.28 Current Ratio3.96 Quick Ratio3.96Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.38 per share Price / Book0.97Profitability EPS (Most Recent Fiscal Year)($1.72) Net Income$-35,650,000.00 Net MarginsN/A Return on Equity-120.77% Return on Assets-84.28%Miscellaneous Employees49 Outstanding Shares23,466,000Market Cap$53.97 million Next Earnings Date3/5/2020 (Estimated) OptionableNot Optionable Receive ALNA News and Ratings via Email Sign-up to receive the latest news and ratings for ALNA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ALNA Rates by TradingView Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions What is Allena Pharmaceuticals' stock symbol? Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA." How were Allena Pharmaceuticals' earnings last quarter? Allena Pharmaceuticals Inc (NASDAQ:ALNA) posted its earnings results on Wednesday, November, 13th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.08. View Allena Pharmaceuticals' Earnings History. When is Allena Pharmaceuticals' next earnings date? Allena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Allena Pharmaceuticals. What price target have analysts set for ALNA? 4 brokers have issued 1 year price targets for Allena Pharmaceuticals' stock. Their forecasts range from $4.00 to $31.00. On average, they anticipate Allena Pharmaceuticals' share price to reach $18.00 in the next twelve months. This suggests a possible upside of 682.6% from the stock's current price. View Analyst Price Targets for Allena Pharmaceuticals. What is the consensus analysts' recommendation for Allena Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allena Pharmaceuticals. Has Allena Pharmaceuticals been receiving favorable news coverage? Media headlines about ALNA stock have been trending somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Allena Pharmaceuticals earned a coverage optimism score of -1.9 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Allena Pharmaceuticals. Are investors shorting Allena Pharmaceuticals? Allena Pharmaceuticals saw a decrease in short interest in January. As of January 31st, there was short interest totalling 553,300 shares, a decrease of 10.2% from the January 15th total of 616,200 shares. Based on an average daily trading volume, of 469,700 shares, the short-interest ratio is presently 1.2 days. Currently, 4.9% of the company's stock are short sold. View Allena Pharmaceuticals' Current Options Chain. Who are some of Allena Pharmaceuticals' key competitors? Some companies that are related to Allena Pharmaceuticals include Verona Pharma (TARA), CASI Pharmaceuticals (CASI), Jounce Therapeutics (JNCE), Windtree Therapeutics (WINT), Fennec Pharmaceuticals (FENC), Dyadic International (DYAI), Solid Biosciences (SLDB), Brainstorm Cell Therapeutics (BCLI), X4 Pharmaceuticals (XFOR), Erytech Pharma (ERYP), Gamida Cell (GMDA), Axcella Health (AXLA), Surface Oncology (SURF), Cidara Therapeutics (CDTX) and Applied Genetic Technologies (AGTC). What other stocks do shareholders of Allena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Clearside Biomedical (CLSD), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), Pieris Pharmaceuticals (PIRS), Amarin (AMRN), Adamas Pharmaceuticals (ADMS) and Anavex Life Sciences (AVXL). Who are Allena Pharmaceuticals' key executives? Allena Pharmaceuticals' management team includes the folowing people: Dr. Alexey L. Margolin, Co-Founder & Chairman (Age 66)Dr. Louis Brenner, Pres, CEO & Director (Age 49)Mr. Edward J. Wholihan, CFO and VP of Fin. & Admin. (Age 59)Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 54)Mr. Hugh Wight, Sr. VP of Technical Operations When did Allena Pharmaceuticals IPO? (ALNA) raised $80 million in an IPO on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Allena Pharmaceuticals' major shareholders? Allena Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.03%), Geode Capital Management LLC (0.45%), Wedbush Securities Inc. (0.21%), Banco Bilbao Vizcaya Argentaria S.A. (0.16%), Algert Global LLC (0.16%) and Goldman Sachs Group Inc. (0.14%). View Institutional Ownership Trends for Allena Pharmaceuticals. Which institutional investors are selling Allena Pharmaceuticals stock? ALNA stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. View Insider Buying and Selling for Allena Pharmaceuticals. Which institutional investors are buying Allena Pharmaceuticals stock? ALNA stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Geode Capital Management LLC, Banco Bilbao Vizcaya Argentaria S.A., Algert Global LLC and Wedbush Securities Inc.. View Insider Buying and Selling for Allena Pharmaceuticals. How do I buy shares of Allena Pharmaceuticals? Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Allena Pharmaceuticals' stock price today? One share of ALNA stock can currently be purchased for approximately $2.30. How big of a company is Allena Pharmaceuticals? Allena Pharmaceuticals has a market capitalization of $53.97 million. The company earns $-35,650,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Allena Pharmaceuticals employs 49 workers across the globe.View Additional Information About Allena Pharmaceuticals. What is Allena Pharmaceuticals' official website? The official website for Allena Pharmaceuticals is http://www.allenapharma.com/. How can I contact Allena Pharmaceuticals? Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577. MarketBeat Community Rating for Allena Pharmaceuticals (NASDAQ ALNA)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 202 (Vote Outperform)Underperform Votes: 193 (Vote Underperform)Total Votes: 395MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2020 by MarketBeat.com StaffFeatured Article: What is an overbought condition?
